A5022292883- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Tryptophan and brain disorders
- Bioinformatics and Genomic Networks
- Mitochondrial Function and Pathology
- Advanced Proteomics Techniques and Applications
- Dementia and Cognitive Impairment Research
- Genetic Neurodegenerative Diseases
- Neurological diseases and metabolism
- Botulinum Toxin and Related Neurological Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Machine Learning in Bioinformatics
- Takotsubo Cardiomyopathy and Associated Phenomena
- Attention Deficit Hyperactivity Disorder
- Ginkgo biloba and Cashew Applications
- COVID-19 and Mental Health
- Cerebral Venous Sinus Thrombosis
- Cholinesterase and Neurodegenerative Diseases
- Banana Cultivation and Research
- Ultrasound and Hyperthermia Applications
- Health, Environment, Cognitive Aging
- Glaucoma and retinal disorders
- Systemic Sclerosis and Related Diseases
- Cardiac Health and Mental Health
Neurology, Inc
2025
Emory University
2012-2024
Emory and Henry College
2024
Emory National Primate Research Center
2023
Johns Hopkins Hospital
2016
Columbia University Irving Medical Center
2011
Yale University
2007
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) representing a wide spectrum AD pathophysiology. Multiplex mass spectrometry identified ~3500 ~12,000 proteins in CSF brain, respectively. Network analysis the brain proteome resolved 44 biologically modules, 15 which overlapped with proteome. markers these...
Abstract The locus coeruleus is the initial site of Alzheimer’s disease neuropathology, with hyperphosphorylated Tau appearing in early adulthood followed by neurodegeneration dementia. Locus dysfunction contributes to pathobiology experimental models, which can be rescued increasing norepinephrine transmission. To test augmentation as a potential disease-modifying therapy, we performed biomarker-driven phase II trial atomoxetine, clinically-approved transporter inhibitor, subjects mild...
Cognitive impairment in the elderly features complex molecular pathophysiology extending beyond hallmark pathologies of traditional disease classification. Molecular subtyping using large-scale -omic strategies can help resolve this biological heterogeneity. Using quantitative mass spectrometry, we measured ∼8000 proteins across >600 dorsolateral prefrontal cortex tissues with clinical diagnoses no cognitive (NCI), mild (MCI), and Alzheimer's (AD) dementia. Unbiased classification MCI AD...
Purpose The present study is a discovery mode proteomics analysis of the membrane‐enriched fraction postmortem brain tissue from A lzheimer's disease ( AD ) and control cases. This aims to validate method identify new proteins that could be involved in pathogenesis potentially serve as biomarkers. Experimental design Liquid chromatography‐tandem mass spectrometry LC ‐ MS / was used analyze human five cases similar age. Biochemical validation specific targets performed by immunoblotting....
Lewy body dementia (LBD), a class of disorders comprising Parkinson's disease (PDD) and with bodies (DLB), features substantial clinical pathological overlap Alzheimer's (AD). The identification biomarkers unique to LBD pathophysiology could meaningfully advance its diagnosis, monitoring, treatment. Using quantitative mass spectrometry (MS), we measured over 9,000 proteins across 138 dorsolateral prefrontal cortex (DLPFC) tissues from University Pennsylvania autopsy collection control, (PD),...
Deep brain stimulation (DBS) for Parkinson's disease (PD) is generally contraindicated in persons with dementia but it frequently performed people mild cognitive impairment or normal cognition, and current clinical guidelines are primarily based on these cohorts.
Previous systems-based proteomic approaches have characterized alterations in protein co-expression networks of unfractionated asymptomatic (AsymAD) and symptomatic Alzheimer’s disease (AD) brains. However, it remains unclear how sample fractionation sub-proteomic analysis influences the organization these their relationship to clinicopathological traits disease. In this proof-of-concept study, we performed a membrane-enriched post-mortem brain samples from pathology-free control, AsymAD, AD...
Lewy body dementia (LBD), a class of disorders comprising Parkinson's disease (PDD) and with bodies (DLB), features substantial clinical pathological overlap Alzheimer's (AD). The identification biomarkers unique to LBD pathophysiology could meaningfully advance its diagnosis, monitoring, treatment. Using quantitative mass spectrometry (MS), we measured over 9,000 proteins across 138 dorsolateral prefrontal cortex (DLPFC) tissues from University Pennsylvania autopsy collection control, (PD),...
Depression is a mortality risk marker for acute coronary syndrome (ACS) patients. We hypothesized that the QT interval, predictor of sudden cardiac death, was related to depressive symptoms in ACS. performed an analysis admission electrocardiograms from hospitalized patients with unstable angina or non-ST elevation myocardial infarction two prospective observational studies depression Depressive were assessed Beck Inventory (BDI), and defined as BDI score ≥10, compared <5. Patients QRS...
Abstract Alzheimer’s disease (AD) features a complex web of pathological processes beyond amyloid accumulation and tau-mediated neuronal death. To meaningfully advance AD therapeutics, there is an urgent need for novel biomarkers that comprehensively reflect these mechanisms. Here we applied integrative proteomics approach to identify cerebrospinal fluid (CSF) linked diverse set pathophysiological in the diseased brain. Using multiplex proteomics, identified >3,500 proteins across 40 CSF...
To assess relationship of tremor reduction and volume lesion post Focused Ultrasound (FUS) therapy in Essential Tremor (ET) Parkinson Disease (PD) patients.
To evaluate the prevalence of gray optic disc crescent within a glaucoma population and influence ethnicity other variables.Consecutive patients white or African American ethnicity, seen in Glaucoma Service Yale Eye Center, were included study. The 2 ethnic groups not matched for refractive error, age, stage glaucoma. Stereodisc photos, suitable detailed evaluation parapapillary features, 1 both eyes selected by investigator. photos masked to investigators, who independently interpreted...
To identify cerebrospinal fluid (CSF) biomarkers of AD linked to a diverse set pathophysiological processes in the diseased brain.
Abstract The hallmark amyloid-β and tau deposition of Alzheimer’s disease (AD) represents only a fraction its diverse pathophysiology. Molecular subtyping using large-scale -omic strategies can help resolve this biological heterogeneity. Using quantitative mass spectrometry, we measured ~8,000 proteins across >600 dorsolateral prefrontal cortex tissues from Religious Orders Study Rush Memory Aging Project participants with clinical diagnoses no cognitive impairment, mild impairment (MCI),...
<b><i>Introduction:</i></b> There is growing interest in using patient-reported outcomes as end points clinical trials, such the progressive supranuclear palsy quality of life (PSP-QoL) scale. However, this tool has not been widely validated and its correlation with motor scales explored. To evaluate potential utility PSP-QoL an outcome, it important to examine relationship a standard scale used neurologic parameters, PSP Rating Scale....
To characterize the behavior of cortical phase amplitude coupling (PAC) during various sleep stages in a Parkinson's disease (PD) population.
Abstract The locus coeruleus (LC) is the initial site of Alzheimer’s disease neuropathology, with hyperphosphorylated Tau appearing in early adulthood followed by neurodegeneration dementia. LC dysfunction contributes to pathobiology experimental models, which can be rescued increasing norepinephrine (NE) transmission. To test NE augmentation as a potential disease-modifying therapy, we performed biomarker-driven phase II trial atomoxetine, clinically-approved transporter inhibitor, subjects...
<title>Abstract</title> Pathogenic variants in the <italic>LRRK2</italic> gene represent most common cause of autosomal dominant Parkinson’s disease (PD) worldwide. We identified p.L1795F variant 14 White/European ancestry PD patients, including two families with multiple affected carriers and seven additional individuals familial using genotyping sequencing data from more than 50,000 through GP2, AMP-PD, PDGENEration, CENTOGENE. All were ancestry, those available shared a haplotype. The...
Objective: To correlate PSP Quality of Life scale (PSP-QoL) ratings within a cross-sectional population with rating (PSPRS) scores. Background: Despite the widespread recognition as distinct disease entity well-defined set disabling symptoms, there have been very few published scales dedicated specifically to assessment this disease. The has emerged useful and broadly validated measurement severity. PSP-QoL, 45-item questionnaire, is only PSP-specific QoL tool, but formally assessed in...